The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

The deal helps move BioNTech’s proposed acquisition of CureVac closer to completion. With the settlement, GSK said it will tender the CureVac shares it owns in support of the $1.25 billion acquisition ...

GlaxoSmithKline plans to split into two businesses -- one for prescription drugs and vaccines, the other for over-the-counter products -- after forming a new joint venture with Pfizer's consumer ...

Pfizer said this week that it expects to go to the FDA with its RSV shot for older adults and in maternal use by year's end. The vaccine's phase 3 read out in infants came out just this week and ...

Pfizer and GSK are running a tight race to tap into the RSV vaccine market, which could exceed $10 billion by 2030. The vaccines are part of both companies' strategies to replace aging drugs that ...

Pfizer, GSK win over CDC advisors for a limited rollout of RSV vaccines Jun. 21, 2023 9:57 PM ET Pfizer Inc. (PFE) Stock GSK By: Dulan Lokuwithana, SA News Editor 6 Comments csraphotography ...

GSK has hired one of the scientists behind Pfizer's mRNA COVID-19 shot, Phil Dormitzer, as its global head of R&D for vaccines and he will join the British drugmaker from Dec. 3, GSK said on Tuesday.

GSK and Pfizer remain major players in the global vaccines market as well. Although both companies experienced sales declines in the second quarter due to the COVID-19 pandemic, this should be ...

Aug 2 (Reuters) - British biopharmaceutical giant GSK GSK.L sued Pfizer PFE.N in federal court in Delaware on Wednesday, alleging that Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo ...

Pfizer Inc. (NYSE: PFE) and GlaxoSmithKline plc (NYSE:GSK) today announced they have entered into an agreement to create a premier global consumer hea ...

(Reuters) - GSK has hired one of the scientists behind Pfizer's mRNA COVID-19 shot, Phil Dormitzer, as its global head of R&D for vaccines and he will join the British drugmaker from Dec. 3, GSK ...